Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab extension study in nAMD (TALON Extension)
NCT04597632Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Primary endpoints: Duration of the Last Interval With no Disease Activity up to Week 56 and Average Change in BCVA From Baseline to Week 52 and Week 56 for the Study Eye. Started Dec 2020; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04597632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597632.